Dr. Henriett Butz is a leading molecular geneticist specializing in hereditary cancer syndromes, tumor progression, and endocrine-related malignancies. Her research emphasizes non-coding RNAs, epigenetic modifications, and rare genetic variants, leveraging next-generation sequencing and integrative bioinformatics to uncover novel biomarkers and therapeutic targets. She has contributed extensively to translational oncology, bridging laboratory discoveries with clinical applications, including studies on triple-negative breast cancer, glucocorticoid receptor signaling, and tumor-stroma interactions. With 92 publications, 2,043 citations across 1,760 documents, and an h-index of 24, Dr. Butz demonstrates sustained research excellence and a strong global scientific impact in cancer genomics and molecular medicine.